Sugi Predict

Sugi Predict / Compounds / SCHEMBL286531

SCHEMBL286531

SCHEMBL286531

COC(=O)c1cc(N)n[nH]1

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.65
▸ GAA P10253 1/20 0.54
▸ ALPL P05186 11/20 0.53
▸ MAPT P10636 6/20 0.53
▸ RAB9A P51151 3/20 0.53
▸ POLB P06746 1/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ NPC1 O15118 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ CYP1A2 P05177 1/20 0.46
▸ HTT P42858 1/20 0.44
▸ TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL286530 0.98 MAPK1 (0.62) MAPK1GAAALPLMAPTRAB9A
SCHEMBL14397331 0.86 MAPK1 (0.50) MAPK1GAAALPLMAPTRAB9A
SCHEMBL4311802 0.80 ALPL (0.55) GAAALPLMAPTRAB9ASMN1; SMN2
Trifluoroacetic Acid SCHEMBL13387751 0.79 GAA (0.43) MAPK1GAAALPLMAPTRAB9A
SCHEMBL68056 0.78 MAPK1 (1.00) MAPK1GAAALPLMAPTRAB9A
SCHEMBL171413 0.78 MAPK1 (0.67) MAPK1GAAALPLMAPTRAB9A
SCHEMBL285996 0.78 MAPK1 (0.67) MAPK1GAAALPLMAPTRAB9A
SCHEMBL17641610 0.78 — —
SCHEMBL20517628 0.77 MAPK1 (0.65) MAPK1GAAALPLMAPTRAB9A
SCHEMBL21630583 0.77 MAPK1 (0.65) MAPK1GAAALPLMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111542523-B Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2024-03-29 — — CN disclosed
EP-3704120-B1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC (US) 2024-03-06 — — EP disclosed
US-11459338-B2 Heterocyclic compounds as PRMT5 inhibitors JUBILANT EPISCRIBE LLC (US) 2022-10-04 — — US disclosed
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC 2021-12-02 — — US disclosed
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC 2021-12-02 — — US disclosed
EP-3704120-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS Jubilant Episcribe LLC (US) 2020-09-09 — — EP disclosed
CN-111542523-A Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2020-08-14 — — CN disclosed
WO-2019102494-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2019-05-31 — — WO disclosed
WO-2019102494-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2019-05-31 — — WO disclosed
US-20170145034-A1 ALKYNYL ALCOHOLS AND METHODS OF USE GENENTECH, INC. (US) 2017-05-25 — — US disclosed
WO-2008021924-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-21 — — WO disclosed
WO-2007139860-A2 HETEROBICYLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS, INC. (US) 2007-12-06 — — WO disclosed
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
WO-2007044410-A1 PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2007-04-19 — — WO disclosed
US-7196111-B2 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents SCHERING CORPORATION (US) 2007-03-27 — — US disclosed
US-20060094706-A1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION 2006-05-04 — — US disclosed
CN-1671710-A Pyrazolo[1,5a]pyrimidine compounds as antiviral agents NEOGENESIS PHARMACEUTICALS INC (US) 2005-09-21 — — CN disclosed
EP-1511751-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS Neogenesis Pharmaceuticals, Inc. (US) 2005-03-09 — — EP disclosed
US-20040038993-A1 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents NEOGENESIS PHARMACEUTICALS, INC. 2004-02-26 — — US disclosed
WO-2003101993-A1 PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS NEOGENESIS PHARMACEUTICALS, INC. (US) 2003-12-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ADAMTS4, ADAMTS1, ADAMTS5 MAPK1 4632/4885GAA 504/4885ALPL 3616/4885
US-20170145034-A1 ALKYNYL ALCOHOLS AND METHODS OF USE NFKB2, NFKB1, RELA MAPK1 343/4885GAA 1695/4885ALPL 3437/4885
US-11459338-B2 Heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 MAPK1 576/4885GAA 3971/4885ALPL 3702/4885
US-20040038993-A1 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents RNGTT, PNP, ZC3HAV1 MAPK1 2589/4885GAA 1017/4885ALPL 2175/4885
US-20060094706-A1 Pyrazolopyrimidines as protein kinase inhibitors CDKN1A, EIF2AK2, DCK MAPK1 280/4885GAA 1918/4885ALPL 3365/4885
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 MAPK1 576/4885GAA 3971/4885ALPL 3702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.